AI is transforming biotechnology. Eli Lilly and Metis TechBio have announced a drug delivery research partnership with potential payments of up to $1.1 billion. Explore how AI-powered lipid nanoparticle technology could shape pharmaceutical innovation and create new opportunities in STEM.
Trending
- Eli Lilly Partners With Metis TechBio in AI-Driven Drug Delivery Deal Worth Up to $1.1 Billion
- Amazon Introduces TorchNeuron to Simplify AI Development on Its Trainium Chips
- Anthropic Proposes Public Benefit Fund as AI Companies Face Growing Questions About Social Impact
- Tenstorrent Raises $1.5 Billion as the Race for AI Computing Infrastructure Intensifies
- Why Major Websites Are Restricting AI Agents—and What It Means for the Future of Automation
- Miami-Founded Dapta Raises $6 Million as AI Sales Automation Gains Momentum Among Small Businesses
- Google Expands AI News Partnerships to More Than 400 Publications, Signaling a New Era for Digital Publishing
- OpenFX Ventures Creates New Investment Opportunities for Fintech Founders
